Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F24%3A43921329" target="_blank" >RIV/00023752:_____/24:43921329 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43927596

Výsledek na webu

<a href="https://www.cambridge.org/core/journals/european-psychiatry/article/trajectories-of-daily-antipsychotic-use-and-weight-gain-in-people-hospitalized-for-the-first-episode-of-psychosis/5824D9F54E97FD375F533F9B4EC46B50" target="_blank" >https://www.cambridge.org/core/journals/european-psychiatry/article/trajectories-of-daily-antipsychotic-use-and-weight-gain-in-people-hospitalized-for-the-first-episode-of-psychosis/5824D9F54E97FD375F533F9B4EC46B50</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1192/j.eurpsy.2024.1761" target="_blank" >10.1192/j.eurpsy.2024.1761</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis

Popis výsledku v původním jazyce

Background We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia.Methods We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors.Results Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications.Conclusions Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

Název v anglickém jazyce

Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis

Popis výsledku anglicky

Background We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia.Methods We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors.Results Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications.Conclusions Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30215 - Psychiatry

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Psychiatry

ISSN

0924-9338

e-ISSN

1778-3585

Svazek periodika

67

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

9

Strana od-do

"e59"

Kód UT WoS článku

001319563400001

EID výsledku v databázi Scopus

2-s2.0-85204941253